Laura Bio

Dr. Laura Bio

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2024 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Closed access
PDF file
CACamila Aparicio
Camila Aparicio
ZWZachary I Willis
Zachary I Willis
MNMari M Nakamura
Mari M Nakamura
JWJoshua Wolf
Joshua Wolf
CLCordell Little
Cordell Little
COCarlos R Oliveira
Carlos R Oliveira
Background: Risk stratification is a cornerstone of the Pediatric Infectious Diseases Society COVID-19 treatment guidance. This systematic review and meta-analysis aimed to define the clinical characteristics and comorbidities associated with critical COVID-19 in children and adolescents. Methods: Two independent reviewers screened the literature (Medline and EMBASE) for studies published through August 31, 2023, that reported outcome data on patients aged ≤21 years with COVID-19. Critical disease was defined as an invasive mechanical ventilation requirement, intensive care unit admission, or death. Random-effects models were used to estimate pooled odds ratios (OR) with 95% confidence intervals (CI), and heterogeneity was explored through subgroup analyses. Results: Among 10,178 articles, 136 studies met the inclusion criteria for review. Data from 70 studies, which collectively examined 172,165 children and adolescents with COVID-19, were pooled for meta-analysis. In previously healthy children, the absolute risk of critical disease from COVID-19 was 4% (95% CI, 1%–10%). Compared with no comorbidities, the pooled OR for critical disease was 3.95 (95% CI, 2.78–5.63) for the presence of one comorbidity and 9.51 (95% CI, 5.62–16.06) for ≥2 comorbidities. Key risk factors included cardiovascular and neurological disorders, chronic pulmonary conditions (excluding asthma), diabetes, obesity, and immunocompromise, all with statistically significant ORs > 2.00. Conclusions: While the absolute risk for critical COVID-19 in children and adolescents without underlying health conditions is relatively low, the presence of one or more comorbidities was associated with markedly increased risk. These findings support the importance of risk stratification in tailoring pediatric COVID-19 management.

23 January 2025 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Closed access
CLChristine R Lockowitz
Christine R Lockowitz
AHAlice J Hsu
Alice J Hsu
KCKathleen Chiotos
Kathleen Chiotos
LBLaura Bio
Laura Bio
ADAimee M Dassner
Aimee M Dassner
PTPranita D Tamma
Pranita D Tamma
The Infectious Diseases Society of America (IDSA) publishes annual guidance on the treatment of antimicrobial-resistant (AMR) gram-negative infections. Within the AMR guidance, suggested dosages of antibiotics for adults infected with AMR pathogens are provided. This document serves as a companion document to the IDSA guidance to assist pediatric specialists with dosing β-lactam agents for the treatment of AMR infections in children. A panel of 13 pediatric infectious diseases specialists, including 11 pharmacists and 2 physicians, reviewed existing pharmacokinetic/pharmacodynamic, animal, and clinical data for newer β-lactam agents that are available in the United States and suggested for the treatment of AMR infections (ie, cefiderocol, ceftazidime-avibactam, ceftazidime-avibactam and aztreonam, ceftolozane-tazobactam, imipenem-cilastatin-relebactam, meropenem-vaborbactam, sulbactam-durlobactam). Suggested dosing for ampicillin-sulbactam is also provided, given complexities in dosing for carbapenem-resistant Acinetobacter baumannii infections. Consensus-based suggested dosing for β-lactam agents used to treat AMR infections in neonates, infants, children, and adolescents and relevant supporting evidence are provided. Content is up to date as of December 1, 2024. Gaps and limitations to existing data are discussed. Optimizing antibiotic dosing is critical to improving the outcomes of children with AMR infections.

10 February 2024 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Open access
PDF file
ZWZachary I Willis
Zachary I Willis
COCarlos R Oliveira
Carlos R Oliveira
MAMark J Abzug
Mark J Abzug
BABrenda I Anosike
Brenda I Anosike
MAMonica I Ardura
Monica I Ardura
JWJoshua Wolf
Joshua Wolf
Background: Since November 2019, the SARS-CoV-2 pandemic has created challenges for preventing and managing COVID-19 in children and adolescents. Most research to develop new therapeutic interventions or to repurpose existing ones has been undertaken in adults, and although most cases of infection in pediatric populations are mild, there have been many cases of critical and fatal infection. Understanding the risk factors for severe illness and the evidence for safety, efficacy, and effectiveness of therapies for COVID-19 in children is necessary to optimize therapy. Methods: A panel of experts in pediatric infectious diseases, pediatric infectious diseases pharmacology, and pediatric intensive care medicine from 21 geographically diverse North American institutions was re-convened. Through a series of teleconferences and web-based surveys and a systematic review with meta-analysis of data for risk factors, a guidance statement comprising a series of recommendations for risk stratification, treatment, and prevention of COVID-19 was developed and refined based on expert consensus. Results: There are identifiable clinical characteristics that enable risk stratification for patients at risk for severe COVID-19. These risk factors can be used to guide the treatment of hospitalized and non-hospitalized children and adolescents with COVID-19 and to guide preventative therapy where options remain available.

21 November 2023 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
LBLaura Bio
Laura Bio
LHLyndsie Hiroshima
Lyndsie Hiroshima
HSHayden T. Schwenk
Hayden T. Schwenk
SGSean Green
Sean Green

30 November 2020 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
LBLaura Bio
Laura Bio
HSHayden T. Schwenk
Hayden T. Schwenk
SCSharon F. Chen
Sharon F. Chen
SCSarah Conlon
Sarah Conlon
AGAmy Gallo
Amy Gallo
HGHayley A. Gans
Hayley A. Gans

16 September 2022 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Closed access
PDF file
DYDiana Yu
Diana Yu
LBLaura Bio
Laura Bio
Selection of an antibiotic and dosing regimen requires consideration of multiple factors including microbiological data, site of infection, pharmacokinetics, and how it relates to the pharmacodynamic target. Given the multiple dosage regimens of amoxicillin with/without clavulanate and cephalexin, we review the principles of dose selection from a pharmacist’s perspective.